Case | HBS Case Collection | January 2005 (Revised March 2006)

Molecular Insight Pharmaceuticals, Inc.

by Richard G. Hamermesh and Edwin W. Parkinson III

Abstract

Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing. Should it continue its current strategy or change its approach? Includes color exhibits.

Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Health Industry;

Citation:

Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)